An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium

被引:0
作者
Schiere, S [1 ]
Proost, JH [1 ]
Roggeveld, J [1 ]
Wierda, M [1 ]
机构
[1] Univ Groningen Hosp, Dept Anesthesiol, Res Grp Expt Anesthesiol & Clin Pharmacol, NL-9700 RB Groningen, Netherlands
关键词
neuromuscular non-depolarizing agents; mivacurium; pharmacology; pharmacokinetics; pharmacodynamics; cholinesterases;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background and objective: The time course of action of mivacurium does not correlate with its rapid breakdown by plasma cholinesterase. Pharmacokinetic-pharmacodynamic (PK-PD) modelling was applied to obtain more insight in the concentration-effect relationship. Methods: Fourteen patients between 25 and 55 yr, undergoing non-major surgery, American Society of Anesthesiologists Grade I-II, were included. All patients received thiopentone/fentanyl/isoflurane/oxygen/nitrous oxide anaesthesia. Neuromuscular block was monitored mechanomyographically using single twitch stimulation (0.1 Hz). Mivacurium was administered as a short-term infusion, mean (standard deviation) duration 4.7 (1.0) min and dose 145 (33) mug kg(-1). Arterial blood samples were obtained, and plasma was analysed using high performance liquid chromatography. PK-PD modelling was performed using an iterative Bayesian two-stage approach, assuming that the trans-trans and cis-trans isomers are equally potent. Results: A PK-PD model with an effect compartment linked to plasma did not fit to the data satisfactorily. A model using an interstitial space compartment between plasma and effect compartment fitted significantly better. Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 mug L-1 (29%) and gamma 3.7 (22%). Conclusions: The PK-PD behaviour of mivacurium could be described using a model with an interstitial space compartment interposed between plasma and effect compartment. This model shows that the time course of mivacurium is mainly governed by the concentration decline in this interposed compartment and only indirectly related to the rapid plasma clearance.
引用
收藏
页码:882 / 891
页数:10
相关论文
共 30 条
[1]  
Akaike H., 1976, MATH SCI, V14, P5
[2]   Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block [J].
Beaufort, TM ;
Nigrovic, V ;
Proost, JH ;
Houwertjes, MC ;
Wierda, JMKH .
ANESTHESIOLOGY, 1998, 89 (03) :707-714
[3]   Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling? [J].
Beaufort, TM ;
Proost, JH ;
Kuizenga, K ;
Houwertjes, MC ;
Kleef, UW ;
Wierda, JMKH .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1999, 27 (02) :173-190
[4]   A comparison of a Bayesian population method with two methods as implemented in commercially available software [J].
Bennett, JE ;
Wakefield, JC .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (04) :403-432
[5]   RECOVERY OF MIVACURIUM AND DOXACURIUM VERSUS VECURONIUM IN THE ISOLATED FOREARM [J].
CAMPKIN, NTA ;
HOOD, JR ;
FELDMAN, SA .
ANAESTHESIA, 1994, 49 (06) :501-502
[6]   A KINETIC-DYNAMIC MODEL TO EXPLAIN THE RELATIONSHIP BETWEEN HIGH POTENCY AND SLOW ONSET TIME FOR NEUROMUSCULAR BLOCKING-DRUGS [J].
DONATI, F ;
MEISTELMAN, C .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (05) :537-552
[7]   Mivacurium arteriovenous gradient during steady state infusion in anesthetized patients [J].
Ezzine, S ;
Donati, F ;
Varin, F .
ANESTHESIOLOGY, 2002, 97 (03) :622-629
[8]   SENSITIVITY TO 2ND DOSE OF MIVACURIUM [J].
FELDMAN, SA ;
HOOD, JR ;
CAMPKIN, NTA ;
REHM, S .
ANAESTHESIA, 1994, 49 (08) :671-674
[9]  
FELDMAN SA, 1993, ANAESTH PHARM REV, V1, P81
[10]   PHARMACODYNAMICS OF NON-DEPOLARIZING NEUROMUSCULAR BLOCKING-AGENTS [J].
HULL, CJ .
BRITISH JOURNAL OF ANAESTHESIA, 1982, 54 (02) :169-182